business
Hantavirus cases spark surge in pharma and biotech stocks — here’s why
Key takeaways
- Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
- Several pharmaceutical stocks surged on Monday as investors assessed which company might be best primed to tackle an outbreak of the hantavirus.
- The public health risk for the virus is low, according to the WHO and other health authorities have noted that human transmission is rare.
Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
Several pharmaceutical stocks surged on Monday as investors assessed which company might be best primed to tackle an outbreak of the hantavirus.
The World Health Organization flagged an outbreak of hantavirus, a fatal and viral respiratory disease spread by rodents, on May 2, after some passengers caught it on a Dutch-flagged expedition cruise ship, the MV Hondius, which was sailing the Atlantic.
Article preview — originally published by CNBC. Full story at the source.
Read full story on CNBC →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from CNBC alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop